The global intravenous solutions market size is anticipated to reach USD 28.2 billion by 2033, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 9.57% from 2026 to 2033. The high prevalence of preterm births, especially in emerging economies such as India and China, is expected to drive market growth during the forecast period. According to WHO, 1 in 10 babies are born preterm, and this is a global concern. Thus, the high incidence of preterm births in emerging economies, improved healthcare infrastructure, and growing healthcare expenditure & patient awareness are expected to be high impact rendering drivers of the market during the forecast period.
The use of parenteral lipid emulsions is driven by the extensive focus of various authorities to limit preterm birth mortality. As of 2021, the preterm birth rate in the U.S. was about 10.5%. Moreover, the annual societal, and economic cost was estimated at USD 25.2 billion for preterm births. Hence, the presence of many neonates requiring supplementary postbirth nutrition is expected to boost the market demand over the forecast period.
In addition, several studies justify the use of parenteral nutrition for patients suffering from malnutrition problems, which increased during the pandemic, leading to market growth. For instance, according to an article published in the Journal of the Academy of Nutrition and Dietetics, many patients admitted to the ICU for COVID-19 treatment suffer from acute malnourishment. Hence, the usage of parenteral nutrition products is expected to increase in the market during the pandemic.
In COVID-19-positive patients, high deficiency of specific micronutrients and vitamins has been reported to be detrimental. Thus, intravenous administration is recommended in such patients to meet the recommended dietary intake. Physicians and nutrition specialists preferred parenteral nutrition over enteral nutrition in COVID-19 patients since enteral nutrition specifically requires the setup of nasogastric tubes, which hampers the noninvasive ventilation provided to COVID-19 patients. The increased risk of nutritional solution aspiration and underfeeding in hospitalized patients for COVID-19 has led to increased adoption of parenteral nutrition.
Request a free sample copy or view report summary: Intravenous Solutions Market Report
Based on type, the market is categorized into Total Parenteral Nutrition (TPN) and Peripheral Parenteral Nutrition (PPN).
Based on nutrients, the single-dose amino acids segment held the largest share of the IV solutions market in 2025.
Based on end use, the home segment held the dominant market share in 2025 and is expected to grow at the fastest CAGR during the forecast period.
North America intravenous solutions industry dominated the global market in 2025 in terms of revenue share.
Grand View Research has segmented the global intravenous solutions market on the basis of type, nutrient, end use, and region:
Intravenous Solutions Type Outlook (Revenue, USD Million, 2021 - 2033)
Total Parenteral Nutrition
Peripheral Parenteral Nutrition
Intravenous Solutions Nutrients Outlook (Revenue, USD Million, 2021 - 2033)
Carbohydrates
Vitamins & Minerals
Single-dose Amino Acids
Parenteral Lipid Emulsion
Others
Intravenous Solutions End Use Outlook (Revenue, USD Million, 2021 - 2033)
Home
Hospitals
Infusion Centers
Intravenous Solutions Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Intravenous Solutions Market
Fresenius Kabi AG
B. Braun SE
Baxter
Otsuka Pharmaceutical Co., Ltd.
Pfizer, Inc.
JW Life Science
Vifor Pharma
ICU Medical, Inc.
"The quality of research they have done for us has been excellent..."